Viking Therapeutics Inc (NASDAQ:VKTX) finished Friday with a subtraction of -$0.15 to close at $11.07, a downside of -1.34 percent. An average of 2,895,800 shares of common stock have been traded in the last five days. There was a fall of -$1.81 in the past week, and it reached a new high 50 times over the past 12 months. The last 20 days have seen an average of 2,248,620 shares traded, while the 50-day average volume stands at 1,835,800.
VKTX stock has decreased by -19.05% in the last month. The company shares reached their 1-month lowest point of $10.66 on 09/28/23. With the stock rallying to its 52-week high on 05/23/23, shares of the company touched a low of $2.62 and a high of $25.72 in 52 weeks. It has reached a new high 29 times so far this year and achieved 17.77% or $1.67 in price. In spite of this, the price is down -56.96% from the 52-week high.
Insider Transactions
VKTX stock investors should be aware that Viking Therapeutics Inc (VKTX) stock had its last reported insider trading activity 137 days ago on May 16. In this transaction, the insider spent $1,000,000. Director, MACARTNEY LAWSON, disposed of 16,000 shares at a price of $24.00 on May 16. The insider now owns more than $384,000 worth of shares. Prior to that, President & CEO Lian Brian went on to Sale 45,000 shares at $22.45 each on May 01. An amount of $1,010,250 was transacted.
Valuation Metrics
Viking Therapeutics Inc (VKTX) stock’s beta is 0.58. Other valuation ratios to consider include the price-to-book (PB) ratio at 2.87.
Financial Health
The quick ratio of Viking Therapeutics Inc for the three months ended June 29 was 29.63, and the current ratio was 29.63, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29.
Earnings Surprise
The company posted a net income of -$19.23 million in the quarter, while revenues of -$19.53 million were grew 9.36%. The analyst consensus anticipated Viking Therapeutics Inc’s latest quarter earnings to come in at -$0.19 per share, but it turned out to be -$0.19, a 0.00% surprise. Shareholders own equity worth $100.03 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Viking Therapeutics Inc (VKTX) price momentum. RSI 9-day as of the close on 29 September was 23.52%, suggesting the stock is oversold, with historical volatility in this time frame at 62.26%.
As of today, VKTX’s price is $11.36 -14.05% or -$1.81 from its 5-day moving average. VKTX is currently trading -19.84% lower than its 20-day SMA and -51.57% lower than its 100-day SMA. However, the stock’s current price level is -27.17% below the SMA50 and +211.83% above the SMA200.
The stochastic %K and %D were 6.38% and 6.66%, respectively, and the average true range (ATR) was 0.82. With the 14-day stochastic at 7.78% and the average true range at 0.81, the RSI (14) stands at 28.33%. The stock has reached -1.18 on the 9-day MACD Oscillator while the 14-day reading was at -2.09.
Analyst Ratings
The consensus rating for Viking Therapeutics Inc (VKTX) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell VKTX, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 10 others rate it as a “buy”.
What is VKTX’s price target for the next 12 months?
Analysts predict a range of price targets between $28.00 and $40.00, with a median target of $34.00. Taking a look at these predictions, the average price target given by analysts for Viking Therapeutics Inc (VKTX) stock is $33.80.
